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Abstract: The biology and pathogenesis of clear cell carcinoma of the kidney has been 
extensively investgated, and the role of von Hipple-Landau gene inactivation and tumor asso-
ciated angiogenesis is now recognized. Development of vascular endothelial growth factor 
inhibitors and phase 3 clinical trials utilizing this class of agents has produced a new treatment 
paradigm for patients with metastatic renal cell carcinoma (RCC). One of the active regimens 
identified is the combination of bevacizumab and interferon-α. Recently published reports 
provided evidence of the clinical and biologic activity of this therapy. The current manuscript 
reviews the background and rationale for the activity of bevacizumab in RCC, and results from 
recent clinical trials with this agent alone or in combination with targeted agents or cytokines. 
The role of this therapy in contrast to other targeted agents is reviewed, and the potential utility 
as well as questions raised by recent studies are discussed.
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Introduction
Renal cell carcinoma (RCC) accounts for 2% to 3% of all solid tumors in adults, and 
over 50,000 new cases were diagnosed in the United States in 2009.1 The primary 
treatment of localized RCC involves surgical resection or local nonsurgical ablative 
techniques. Systemic therapy is utilized when advanced or metastatic disease is pres-
ent. Recently a new paradigm has been developed for systemic therapy of RCC that 
targets specific pathways in this neoplasm. The role of von Hippel-Lindau (VHL) 
gene inactivation in clear cell RCC2 provided an explanation for the long recognized 
angiogenic features of kidney cancer, and was followed by the development of vascular 
endothelial growth factor (VEGF) pathway inhibitors as a new standard of care for 
patients with metastatic disease. Based on these studies, a new treatment approach 
then developed utilizing drugs targeting components of this pathway. Sunitinib3 and 
temsirolimus4 are considered frontline agents for the management of renal cell carci-
noma. Recently, reports by Escudier et al5 and Rini et al6 have provided evidence the 
combination of bevacizumab and interferon-α (IFN-α) is also an effective strategy 
for initial therapy of metastatic RCC. This review summarizes the rationale, clinical 
data, and the results from contemporary studies, as well as exploring the future role 
of bevacizumab in RCC therapy.
Clear cell carcinoma biology
A growing understanding of the molecular biology of RCC has identified a num-
ber of pathways pertinent to the development and progression of clear cell RCC. Cancer Management and Research 2010:2 84
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Activation of the hypoxia response pathway by mutations 
of the von Hippel-Lindau (VHL) tumor suppressor gene 
produces transcriptional activation of genes important in 
tumor progression, including vascular endothelial growth 
factor (VEGF), a potent promoter of tumor-associated 
angiogenesis.2,7 The VHL gene encodes a 213 amino acid 
protein (pVHL) which functionally regulates the normal 
cellular response to oxygen deprivation. In conditions of 
physiologic oxygen availability and normal VHL gene func-
tion, pVHL is a component of an ubiquitin ligase complex 
that targets a family of protein transcription factors, the 
hypoxia-inducible factors (HIF1α and HIF2α) for proteoly-
sis. Under hypoxic conditions, this interaction is disrupted 
secondary to loss of oxygen-dependent hydroxylation of 
HIF, leading to stabilization of the HIF transcription fac-
tors.8 In the presence of a defective VHL gene and/or loss 
of protein function, the interaction between pVHL and HIF 
is disrupted despite the presence of adequate oxygen. HIF 
is not degraded, is constitutively activated, translocates to 
the nucleus, and promotes transcription of various hypoxia-
inducible genes.9 Several of these are critical mediators of 
tumorigenesis, such as VEGF.9
In sporadic (non-inherited) RCC, VHL gene allele dele-
tion (loss of heterozygosity) has been demonstrated in 84% 
to 98% of sporadic renal tumors, and examination of RCC 
tumors for mutation in the remaining VHL allele has been 
observed in 34% to over 80% of clear cell RCC tumors.10,11 
VHL gene inactivation in RCC may also occur through 
gene silencing by methylation.12 Taken together, the above 
data suggest that VEGF inhibitors should be a focus of drug 
development in this neoplasm.
Vascular endothelial growth  
factor (VEGF)
In 1948, Michaelson identified a soluble “angiogenic factor X” 
which promoted the growth of retinal vessels.13 This factor was 
eventually identified as VEGF. It was also referred to as VPF 
(vascular permeability factor) and functions as an important 
regulator of endothelial cell biology. VEGF was identified in 
1989 as a secreted mitogen of endothelial growth,14 and is now 
recognized as a dominant factor in tumor growth and develop-
ment. VEGF regulates vascular endothelial cells, promoting 
both proliferation and new vessel formation. This ligand-medi-
ated response occurs during normal physiological angiogenesis, 
such as wound healing and uterine decidua formation, as well 
as in pathologic situations such as cancer. Tumor-associated 
angiogenesis is dependent on secreted VEGF to promote exist-
ing vessel ingrowth into the tumor as well as neovascularization. 
Because of the importance of VEGF in this process, it has a 
critical role in tumor associated angiogenesis.
VEGF defines a family of related peptides, each with 
restricted tissue expression and receptor specificity. VEGF-A 
is structurally related to the platelet-derived growth factor 
(PDGF) family, sharing homology with both PDGF-A and 
PDGF-B. Originally, VEGF-A was identified as a 45 kD 
protein produced by pituitary cells.15 The active portion of the 
protein identified was the 26 amino acid signal sequence at 
the N terminus of the molecule. The VEGF-A gene is located 
at 6p21.3.16 Human VEGF-A has at least 9 subtypes due to 
the alternative splicing of a single gene.17,18
The various activities of the VEGF isoforms is an area of 
active investigation. Selected isoforms such as VEGF-165b 
can act in a dominant negative fashion. This isoform binds to 
VEGF-R2 with the same affinity as VEGF165, but does not 
activate downstream signaling pathways.17 Mice engineered 
to express only VEGF121, die within the first 2 weeks of life 
secondary to ischemic cardiomyopathy and failure of myo-
cardial angiogenesis.19,20 In mice lacking VEGF165, severe 
defects in developing blood vessels are seen.
VEGF is primarily produced and secreted by fibroblasts.21 
Its expression is regulated by a series factors including growth 
factors, p53 mutation, estrogen receptor activation, thyroid 
stimulating hormone, nitric oxide, and hypoxia. Inappropri-
ate activation of the hypoxia response pathway, is the major 
mechanism of VEGF transcriptional regulation in renal cell 
carcinoma.2 The HIFα subunits activated by either inactiva-
tion of VHL or hypoxia heterodimerize with a constitutively 
available HIF1β (aryl hydrocarbon receptor nuclear transfer-
ase, ARNT). This complex can then bind a hypoxia response 
element, and induce VEGF transcription.22
VEGF function
Secreted VEGF is a mitogen for capillary and vascular 
endothelial cells.15,23 It stimulates proliferation of endothelial 
cells, through binding and dimerization of cell surface recep-
tors. FLT1 (VEGFR1) and KDR/FLK1 (VEGFR2) are the 
major receptors which bind VEGFA. They are only found on 
endothelial cells, and it appears VEGF isoforms compete for 
receptor binding. Specifically, VEGF145, the major tumor-
associated isoform, will inhibit the binding of VEGF165 to 
the KDR/FLK1 receptor.24 Additionally, VEGF regulates the 
permeability of blood vessels,25 in a dose dependent man-
ner. Increased vessel permeability is a critical step for the 
abnormal transport of molecules and cells across the blood 
vessel wall and, therefore, may be a crucial abnormality in 
tumor growth and metastasis.26Cancer Management and Research 2010:2 85
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Bevacizumab:   VEGF  
monoclonal antibody
Bevacizumab (rhuMAb VEGF, Avastin®; Genentech, South 
San Francisco, CA) is a recombinant human monoclonal 
antibody that binds and neutralizes all biologically active 
isoforms of VEGF.27 In vitro studies have demonstrated 
bevacizumab decreases both the survival of human vascular 
endothelial cells (HUVEC) and VEGF-induced HUVEC 
permeability.28 It inhibits proliferation of bovine capillary 
endothelial cells in response to VEGF, and has anti-tumor 
effects against selected sarcoma and breast cancer cell lines.27 
Additionally, bevacizumab has activity against metastases 
in a variety of preclinical models.29 Finally, Rowe et al30 
reported the antibody (A4.6.1) prevented lung metastases 
from Wilm’s tumors implanted into kidneys of nude mice. 
A series of clinical trials were then performed which defined 
the toxicity and efficacy of bevacizumab.
Bevacizumab: clinical trials
Phase 1 trials
The initial clinical evaluation of bevacizumab involved 
a series of phase 1 trials in patients with refractory solid 
tumors. Gordon et al31 reported a phase 1 trial of bevaci-
zumab in patients with metastatic cancer who had failed 
prior therapy. It was administered as a 90-minute intra-
venous (IV) infusion at doses from 0.1 to 10.0 mg/kg on 
days 0, 28, 35, and 42. Twenty-five patients including 7 with 
metastatic RCC were accrued. There were no grade III or 
IV adverse events related to the antibody, and 3 episodes of 
tumor-related bleeding were noted. Bevacizumab Infusions 
were well tolerated without significant toxicity. Grades I and 
II adverse events probably related to bevacizumab included 
asthenia,headache, and nausea. Pharmacokinetic stud-
ies revealed a half-life of 21 days. There were no objec-
tive responses; however, 6/7 RCC patients experienced 
stable disease over the duration of the study. This included 
1 patient with metastatic RCC in whom a minor response 
characterized as 30% reduction of pulmonary and lymph 
node lesions was seen. Bevacizumab was safely adminis-
tered without dose-limiting toxicity at doses ranging up 
to 10 mg/kg, and multiple doses were well tolerated. The 
pharmacokinetic studies indicated that doses of 0.3 mg/kg 
had a half-life similar to that of other humanized antibod-
ies. This initial trial demonstrated a favorable acute toxicity 
profile, and in retrospect suggested activity in RCC.
A second phase 1 trial investigated the safety and phar-
macokinetics of weekly intravenous bevacizumab combined 
with one of three standard chemotherapy regimens.32 
Twelve patients were treated (4 receiving each combination) 
with bevacizumab 3 mg/kg IV weekly for 8 weeks with either 
(1) doxorubicin 50 mg/m2 every 4 weeks; (2) carboplatin at 
area under the curve of 6 plus paclitaxel 175 mg/m2 every 
4 weeks; or (3) fluorouracil 500 mg/m2 with leucovorin 
20 mg/m2 weekly, weeks 1 to 6 every 8 weeks. Grade 3 toxici-
ties attributed to chemotherapy included diarrhea (1 patient), 
thrombocytopenia (2 patients), and leukopenia (1 patient). 
The mean (±SD) peak serum level of bevacizumab was 167 ± 
46 µg/mL, and mean terminal half-life 13 days. One patient 
with refractory RCC received doxorubicin and bevacizumab, 
and had a partial response. The patient received 36 doses of 
antibody with no cumulative or late toxicities noted. This 
study not only demonstrated the safety of bevacizumab com-
bined with chemotherapy, but also again suggested possible 
activity in patients with metastatic RCC.
Phase 2 trials
A series of phase 2 trials were then conducted in patients 
with metastatic RCC, and demonstrated the therapeutic 
activity of bevacizumab in this neoplasm. The initial study 
reported was a randomized phase II trial (Figure 1) in which 
116 patients with treatment-refractory, metastatic clear cell 
RCC received placebo, low dose (3 mg/kg) bevacizumab 
or high dose (10 mg/kg) bevacizumab given intravenously 
every 2 weeks.33 The majority of these patients were cyto-
kine refractory, having received prior high dose interleukin 
(IL)-2. There were 4 partial responses, all in the high dose 
bevacizumab arm (4/39; 10% objective response rate). 
A substantial proportion of patients, however, had tumor 
shrinkage not meeting objective response criteria. Figure 
2 demonstrates tumor burden changes over time for each 
of the three patient cohorts, demonstrating a gradual 
positive effect on tumor burden with increasing doses of 
bevacizumab.34 An intent-to-treat analysis demonstrated a 
significant prolongation of time to progression in the high 
dose bevacizumab arm compared to placebo (4.8 vs 2.5 
months; P  0.001 by log rank test). In the high dose beva-
cizumab arm, hypertension of any grade occurred in 36% of 
patients, and grade 3 hypertension, defined as hypertension 
not controlled by one standard medication, was observed in 
21% of patients. Asymptomatic proteinuria without renal 
insufficiency was noted in 64% of patients in the high 
dose bevacizumab arm. All toxicities were reversible with 
cessation of therapy. The optimal duration of treatment 
with an agent such as bevacizumab was unclear, but pre-
clinical studies had demonstrated VEGF maintained tumor Cancer Management and Research 2010:2 86
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vessel morphology, providing a rationale for continuous 
anti-VEGF therapy.35 In the study reported by Yang et al33 
administration of bevacizumab was continued for over three 
years in four patients with prolonged disease stability.36 
The toxicity in these patients was limited to proteinuria 
with normal renal function, and demonstrated long-term 
continuous administration was possible.
Bevacizumab was then investigated in combination with 
an anti-epidermal growth factor receptor (EGFR) inhibitor. 
Pre-clinical investigations in a human RCC xenograft model 
High dose = 10 mg/kg (n = 39)
ORR – 10%
Low dose = 3 mg/kg (n = 37)
ORR – 0%
Placebo  (n = 40)
ORR – 0%
•   1° end points: TTP and ORR
•   2° end point: OS
•   Study arms were balanced 
     for demographics
mRCC patients
ECOG PS < 2
clear cell Carcinoma
All patients have
prior therapy
(mostly IL-2)
(N = 116)
 
Figure 1 Study schema for phase 2 randomized trial of bevacizumab or placebo in patients with previously treated metastatic renal cell carcinoma.
Drawn from data of Yang JC et al.33
Abbreviations: ORR, overall response rate;   TTP, time to progression; OS, overall survival.
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Figure 2 Phase 2 randomized trial of bevacizumab (low dose – 3.0 mg/kg iv every 2 weeks; high dose – 10.0 mg/kg iv every 2 weeks) or placebo. The individual panels illustrate 
the change in tumor burden expressed as percent compared to baseline over time (weeks of treatment). Each line represents an individual patient. The findings demonstrate 
the higher frequency of tumor reduction in the patients receiving high dose bevacizumab.
Drawn from data of Elaraj et al.34Cancer Management and Research 2010:2 87
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demonstrated treatment with bevacizumab and erlotinib, 
a small molecule EGFR inhibitor, produced tumor growth 
inhibition.37 TGF-α is a VHL-regulated growth factor for 
RCC, with biologic effects mediated through EGFR.38 In view 
of these observations, a phase 2 clinical trial in metastatic 
RCC with bevacizumab 10 mg/kg IV every 2 weeks in com-
bination with erlotinib 150 mg daily was conducted.39 A 25% 
objective response rate and 61% stable disease rate was noted 
with many of the stable disease patients experiencing minor 
tumor regression. After a median follow-up of 15 months, 
survival at 18 months was 60%. Treatment associated adverse 
events were generally mild to moderate. The most common 
severe toxicities included rash (13%), diarrhea (13%) and 
hypertension (8%).
A second phase 1/2 trial employed combined VEGF, 
EGFR and PDGF-R blockade, and utilized combined 
bevacizumab 10 mg/kg IV every 2 weeks, erlotinib 
150 mg by mouth daily, and imatinib 400 mg by mouth 
daily.40 The investigators reported a 9% response rate 
with 61% disease stabilization by RECIST criteria. 
Although tolerable for most patients, the toxicity was 
increased when compared to the experience with two 
agents, bevacizumab and erlotinib. In particular, the 
frequency and severity of grade 3 and 4 diarrhea (29%) 
and acneiform skin rash (27%) were increased with the 
addition of imatinib.
Since previous reports in which EGFR inhibitors alone 
were administered to patients with metastatic RCC did not 
demonstrate clinical activity,41 and these combination studies 
were interpreted as suggesting potential synergistic activity 
of bevacizumab and erlotinib.
Based on these preliminary reports39,40 a randomized, 
multicenter, double-blind phase 2 trial (Figure 3) at 21 sites 
in the United States, was conducted to further evaluate the 
efficacy of this combination as first-line therapy for metastatic 
RCC.42 Eligibility criteria included predominant (50%) 
clear cell histology, prior nephrectomy, measurable disease, 
and required patients to have either favorable or intermedi-
ate Memorial Sloan-Kettering Cancer Center (MSKCC) 
prognostic category.43 Treatment included bevacizumab 10 
mg/kg, IV every 2 weeks, and either oral erlotinib 150 mg or 
a placebo until progression, toxicity, or for a maximum of 104 
weeks. The primary endpoints were progression-free survival 
(PFS) and overall response rate (ORR). One hundred and four 
patients were enrolled (Figure 3), and the median follow-up 
was 9.8 months. Median PFS was similar in the two treatment 
arms: 8.5 months with bevacizumab alone and 9.9 months for 
the combination (hazard ratio [HR] = 0.86, P = 0.58). At 12 
months from time of randomization, 40% of patients in the 
bevacizumab arm versus 45% in the bevacizumab plus erlo-
tinib arm were progression-free. The pooled median PFS for 
the 104 patients entered was 8.6 months. Objective response 
•   Primary endpoints: PFS and ORR
–   Landmark analysis at 9 months after last patient enrolled to estimate PFS and
     ORR (by RECIST)
•   Secondary endpoints:  
–   Duration of response, overall survival, time to symptom progression
•   Treatment duration – 104 weeks
Subjects with metastatic
RCC
(clear cell Carcinoma);
Treatment-naive
(n = 104)
 
Bevacizumab (10 mg/kg IV q2 weeks) + 
placebo × 24 months
Bevacizumab (10 mg/kg IV q2 weeks) + 
Erlotinib (150 mg/day) × 24 months
1:1
Figure 3 Study schema for phase 2 randomized trial of bevacizumab plus placebo versus bevacizumab plus erlotinib in patients with treatment-naïve metastatic renal cell 
carcinoima.
Drawn from data of Bukowski et al.41
Abbreviations: PFS, progression-free survival; ORR, overall response rate.Cancer Management and Research 2010:2 88
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rates were also similar in the arms: 13% versus 14% respec-
tively (P = 1.0). At 12 months from randomization, 83% of 
patients treated with bevacizumab were alive, versus 70% for 
patients receiving the combination.
Treatment was well tolerated, and only one therapy-related 
death occurred. The most common Grade 3/4 adverse events 
(5% of patients) were hypertension, rash, diarrhea, and 
proteinuria. Adverse events associated with erlotinib (rash, 
diarrhea) were observed only in the arm containing erlotinib 
(16% and 7.8% of patients, respectively). Similar rates of hyper-
tension and proteinuria, known toxicities associated with beva-
cizumab, were present in the two treatment arms. No evidence 
of enhanced toxicity was apparent. This study suggested one or 
more of the following: 1) erlotinib does not add to the efficacy of 
bevacizumab, 2) single-agent activity of bevacizumab has been 
underestimated, and/or 3) the randomized phase 2 trial design 
was underpowered to detect a small benefit with combination 
therapy. The role of bevacizumab in RCC remained unclear, 
and subsequently a series of phase 3 trials were conducted that 
clearly demonstrated its clinical activity.
Phase 3 trials
The phase 3 trials investigating bevacizumab in advanced 
clear cell carcinoma patients were then conducted utilized 
combination therapy with IFN-α, and conclusively 
  demonstrated the activity of this antibody (Figure 4). In the 
US, an Intergroup phase 3 open label trial (CALGB 90206) 
investigating the addition of bevacizumab to IFN-α has 
been reported,6 and in Europe, a similar trial which, how-
ever, was blinded and placebo controlled (AVOREN)5 has 
been reported. The data from this latter study supported the 
approval of bevacizumab plus IFN-α treatment for metastatic 
RCC by both the Food and Drug Administration (FDA) and 
the European Medicines Agency (EMEA).
CALGB 902066 was a two-arm open-label study in which 
patients with metastatic clear cell RCC without prior systemic 
therapy were randomized to either low dose IFN-α2b (Intron® 
A; Schering-Plough, Kenilworth, NJ, USA), 9 MIU subcuta-
neously 3 times weekly, or the same dose and schedule of IFN-
α2b in combination with bevacizumab, 10 mg/kg IV every 2 
weeks. Preliminary preclinical or clinical data demonstrating 
enhanced efficacy were not available, and the two agents were 
empirically combined. The primary endpoint of the trial was 
overall survival, and it was designed to detect an improvement 
from 13 months with IFN-α alone, to 17 months for the com-
bination. Secondary endpoints included PFS, ORR, and safety. 
The study was reported before the primary endpoint was 
reached, when preliminary results from the AVOREN trial5 
Patient population: metastatic clear cell carcinoma
no prior systemic therapy
CALGB 90206
N = 732
IFN-α 9.0
MIU TIW
IFN-α 9.0 MIU TIW
+
Bevacizumab
10 mg/kg d1,15
Randomize
Randomize
IFN-α 9.0 MIU TIW
(52 weeks)
+
Bevacizumab
10 mg/kg d1,15
IFN-α 9.0 MIU
TIW (52 weeks)
+
Placebo
CALGB 90206a AVORENb
Therapy (arm) IFN-α IFN-α +
bevacizumab
IFN-α +
bevacizumab
IFN-α + placebo
% ORR 13.1% 25.5%
Median PFS 5.2 mos 8.5 mos
Median OS 17.4 mosc 18.3 mosc
31.0% 13.0%
10.2 mos 5.4 mos
23.3 mosd 21.3 mosd
BO17705 (Avoren)
N = 649
Figure 4 Treatment schema and results in phase 3 randomized trials utilizing interferon alpha (IFN-α) with/without bevacizumab. Results of the two studies AVOREN and 
CALGB 90206 are illustrated, demonstrating overall response rates (ORR), median progression-free survival (PFS), and median overall survival (OS).
aRini et al;6 bEscudier et al;5 cRini et al,44 P = 0.069 (stratified log rank); dEscudier et al,45 P = 0.069 (stratified log rank).Cancer Management and Research 2010:2 89
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became available and demonstrated improvement of PFS for 
patients treated with the combination regimen. At that point, 
the CALGB Data Safety Monitoring Board recommended 
release of the PFS data. The median PFS was 8.5 months (95% 
confidence interval [CI] 8.3–14.8) in patients receiving beva-
cizumab plus IFN-α versus 5.2 months (95% CI 5.6–11.4) 
for IFN-α monotherapy (P  0.0001). The hazard ratio for 
progression in patients receiving bevacizumab plus IFN-α 
after adjusting for stratification factors was 0.71 (P  0.0001). 
In 639 patients with measurable disease, the ORR was higher 
in those receiving bevacizumab plus IFN-α (25.5%; 95% 
CI 20.9%–30.6%) compared to individuals treated with 
IFN-α alone (13.1%; 95% CI 9.5%–17.3%; P  0.0001). 
The combination however, produced an increased frequency of 
adverse events compared to cytokine therapy alone. Increased 
fatigue, anorexia, hypertension and proteinuria were reported. 
The survival data from this trial were recently updated.43 
The median OS was 18.3 months (95% CI 16.5–22.5) for 
patients randomized to bevacizumab plus IFN-α and 17.4 
months (95% CI 14.4–20.0, unstratified log rank P = 0.097) 
for IFN-α monotherapy group. The stratified HR was 0.86 
(95% CI 0.73–1.01) for the combination compared to IFN-α 
alone (stratified log-rank P = 0.069). Survival in the various 
MSKCC prognostic groups was also reported. In the favorable 
group, the median OS for bevacizumab plus IFN-α versus 
IFN-α was 32.5 versus 33.5 months (P = 0.524). In MSKCC 
intermediate risk patients, the respective median OS were 
17.7 versus 16.1 months (P = 0.174), in poor risk patients 
6.6 versus 5.7 months (P = 0.245). The final median PFS in 
both treatment groups was reported as 8.4 months versus 4.9 
months (P  0.0001). Fifty-three percent of patients received 
subsequent second-line systemic therapy.
These results were similar to those reported by the 
AVOREN investigators.5 This trial design was more robust, 
and differences included a double blind design, inclusion of 
a placebo infusion, gradual dose escalation of IFN-α over 
3 weeks, requirement for prior nephrectomy, and the presence 
of predominantly clear cell carcinoma in the AVOREN study. 
Results from these two studies are compared in Table 1. In 
both trials, patients treated with IFN-α plus bevacizumab 
appeared to benefit, with significant increases in median 
PFS and ORR noted. The magnitude of improvement seen 
was slighty different, but the varied eligibility criteria and 
patient distribution between prognostic categories, as well 
as variations in experimental design, can potentially explain 
these findings. Of interest, subset analyses in both trials 
failed to demonstrate improved PFS for the poor risk patient 
subset, which represented a very small group (10%) in 
both trials. Based on the AVOREN data, the combination of 
bevacizumab plus IFN-α has been approved for the treatment 
of patients with metastatic RCC by both the EMEA and 
FDA (after independent radiology review). The final AVO-
REN survival data have also been reported.45 At the time of 
this analysis median follow-up was over 20 months in each 
arm. The final median OS stratified for region and MSKCC 
prognostic group was 23.3 months for patients treated with 
in bevacizumab + IFN-α, versus 21.3 months in the IFN-α 
and placebo arm (HR 0.86 [95% CI 0.72–1.04], P = 0.1291). 
No new or unexpected adverse events were observed. More 
patients in the IFN-α plus placebo arm (202, 63%) received 
post-protocol therapy than in the combination arm (180, 
55%). Treatments included tyrosine kinase inhibitors (TKI), 
mTOR inhibitors, cytokines and chemotherapy. Exploratory 
analysis demonstrated the median OS in pts receiving second-
line TKI therapy was 38.6 months in patients initially treated 
with bevacizumab plus IFN-α (n = 96) versus 33.2 months 
in the IFN-α patient group (n = 81) (HR = 0.77 [95% CI 
0.51–1.15], P = 0.1948).
These results demonstrate clinical benefit for patients 
receiving combination therapy, but as is usually the case, raise 
additional questions. The activity of bevacizumab in combi-
nation with IFN-α in patients with metastatic clear cell carci-
noma is clear; however, dose levels of both agents, length of 
therapy, and the role of IFN-α are not addressed except indi-
rectly. In the United States, the FDA suggested the CALGB 
90206 study incorporate a third treatment arm utilizing 
bevacizumab alone, to isolate the effects of both agents. 
Unfortunately, this advice was not followed, and therefore, 
Table 1 Risk group survivals in phase 3 bevacizumab trials
Risk group 
(MSKCC)a
Progression-free survival* Overall survival* 
AVORENb CALGB 90206c AVOREN CALGB 
90206d
Favorable
Bevacizumab + 
IFN-α
12.9 mos 11.1 mos NA 32.5 mos
IFN-α 7.6 mos 5.7 mos NA 33.5 mos
Intermediate
Bevacizumab + 
IFN-α
10.2 mos 8.4 mos NA 17.7 mos
IFN-α 4.5 mos 5.3 mos NA 16.1 mos
Poor
Bevacizumab + 
IFN-α
2.2 mos 3.3 mos NA 6.6 mos
IFN-α 2.1 mos 2.6 mos NA 5.7 mos
*Median; NA – not available.
aMotzer et al43; bEscudier et al5; cRini et al6; dRini et al.44Cancer Management and Research 2010:2 90
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the potential contributions of each agent are unclear. In view 
of the previous phase 2 data with bevacizumab monotherapy 
in untreated patients,42 in which a median PFS in excess of 
9.0 months was noted, it is reasonable to suggest the major 
contribution to efficacy in terms of PFS improvement, may 
be secondary to this agent.
Additionally, preclinical data are not available that address 
the mechanisms potentially responsible for the interactions of 
these two agents. Bevacizumab and IFN-α may have comple-
mentary effects on tumor growth as well as the antitumor 
immunologic response. The concept of immune dysfunction 
related to both local and systemic immunosuppression has 
been repeatedly demonstrated in advanced RCC.46 In pre-
clinical studies, VEGF inhibits the maturation and function 
of dendritic cell,47 and IFN-α can induce maturation and 
cytokine production48 by this cell population. The possibility 
that anti-VEGF therapy combined with IFN-α may interact 
to decrease immune suppression is an attractive hypothesis. 
Finally, since both bevacizumab and low doses of IFN-α 
have antiangiogenic activity,49 the interaction may be at this 
level. The exact nature of this interaction in RCC patients 
is, however, unclear, as is the contribution of each agent 
individually to the clinical results.
In terms of the toxicity produced by bevacizumab plus 
IFN-α, the adverse events appear related to both agents. In 
the AVOREN trial,5 the most commonly reported grade 3 or 
worse adverse events were established IFN-α toxicities 
(eg, fatigue, asthenia, and neutropenia). Adverse events 
occurred in 328 (97%) of those patients who received at 
least one dose of bevacizumab and 287 (94%) of those 
who did not receive bevacizumab. Serious adverse events 
( grade 3) were reported in 98 (29%) patients who received 
bevacizumab and 50 (16%) of those receiving a placebo. The 
proportion of patients who experienced an adverse event that 
led to treatment discontinuation (28%) was higher in the 
bevacizumab plus interferon alfa group than in the control 
group. The incidence of interferon-related toxicities was 
reported as 10% higher per patient-year in the bevacizumab 
plus interferon alfa group than in the control group. Beva-
cizumab-related toxicities (eg, proteinuria, bleeding, and 
hypertension) were seen in the bevacizumab plus IFN-α 
group only.
The dose of IFN-α utilized in the AVOREN trial was 
9 MIU 3 times a week.5 Investigators were permitted to 
gradually escalate IFN-α from 3.0 to 9.0 MIU over a 3-week 
period. During the course of treatment, IFN-α dose reduction 
and/or delay was permitted for  grade 3 toxicity. The IFN-α 
dose was reduced to 6.0 or 3.0 MU in 124 (40%) patients in 
the bevacizumab plus IFN-α group and 94 (30%) patients 
in the control group. An exploratory analysis50 demonstrated 
patients receiving a reduced dose of IFN-α (either 3.0 or 
6.0 MIU) also benefited from treatment. Although IFN-α 
related grade 3/4 toxicity was predefined as a requirement 
for IFN-α dose reduction, it was reported in only 44% and 
41% of patients in the bevacizumab and placebo groups, 
respectively, in the 6 weeks prior to IFN-α dose reduction. 
In the majority of cases, the IFN-α dose was reduced for 
reasons other than grade 3/4 toxicity, including the accumula-
tion of grade 2 IFN-α related events, or based on physician 
or patient preference.
Of those patients who received reduced doses of IFN-α, 
64% underwent 1 dose reduction (to 6 MIU), 31% underwent 
2 dose reductions (to 6.0 MIU, then to 3.0 MIU) and 5% 
dose-reduced directly to 3.0 MIU. Patients in the dose reduc-
tion group spent 62% of the total IFN-α treatment duration 
at 6.0 or 3.0 MIU. Analysis of all patients demonstrated the 
median duration of PFS in patients receiving bevacizumab 
plus IFN-α was double that of patients receiving IFN-α plus 
placebo (HR = 0.63, P  0.0001). An exploratory analysis 
also showed a similar improvement in PFS for patients receiv-
ing reduced IFN-α doses (HR = 0.63, P = 0.0026) and those 
treated with 9.0 MIU (HR = 0.69, P = 0.0007).
PFS rates at 12 months for patients receiving bevaci-
zumab plus IFN-α were 0.524 for the reduced-dose group 
(95% CI 0.436–0.613), 0.427 for the total population (95% 
CI 0.372–0.483), and 0.361 for patients maintaining the 
9.0 MIU IFN-α dose level (95% CI 0.292–0.431). The 
12-month PFS rate was similar in patients who were dose 
reduced to 3.0 MIU IFN (0.668 [95% CI 0.512–0.824]). 
These data are consistent with previous observations sug-
gesting IFN-α efficacy in patients with metastatic RCC is 
not dose related, and indicate lower doses of IFN-α should 
be combined with bevacizumab in future studies.
The pattern of adverse event (AE) reporting demonstrated 
the majority of grade 3 AEs occurred during the first 3 months 
of treatment. A reduction in  grade 3 AEs was observed in 
the 6-week period after IFN-α dose reduction in contrast to 
the 6 weeks prior to dose reduction in the group receiving 
bevacizumab plus reduced-dose IFN-α (44% vs 18%) and 
reduced-dose IFN-α plus placebo (41% vs 10%). This trend 
toward improved safety was consistent across the MSKCC 
risk categories. In view of the recognized lack of IFN-α 
dose-response in RCC, it appears that lower doses will result 
in less toxicity, and possibly preserve efficacy.
The final overall survival analysis has been completed 
for both CALGB 90206 and the AVOREN trials.44,45 The data Cancer Management and Research 2010:2 91
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do not demonstrate significant improvements in median OS 
in either trial, but as in other recently published analyses of 
other targeted agents,51 may be confounded by secondary 
therapy. The effects of bevacizumab plus IFN-α compared to 
IFN-α alone on PFS and median OS in the various MSKCC 
prognostic subgroups are also of interest (see Table 1). The 
subgroup analyses show the major effects are in the favorable 
and intermediate subgroups. The poor risk patient subset 
shows limited if any effect of adding bevacizumab to IFN-α, 
but this group represents 10% of patients in each trial. 
The overall survival subset analyses from CALGB 90206 
shows improvement in the intermediate group, but none in 
the favorable and poor risk categories. This is similar to the 
reported effects of sunitinib on median OS in the favorable 
patient subset, and raises the issue of why no differences 
were seen between IFN-α monotherapy and either sunitinib 
or bevacizumab plus IFN-α. Explanations again include the 
confounding effects of secondary therapy, as well as the indo-
lent behavior RCC clinically and the as yet undefined biologic 
and molecular characteristics of this RCC subtype.
Pharmacoeconomic analyses
In view of the costs associated with targeted therapy for 
advanced RCC patients, it is reasonable to expect improve-
ment in survival as an indicator of benefit. The confounding 
effects of secondary therapy have, however, made results 
from these analyses problematic. CALGB 90206 had as 
its primary endpoint OS, and, the overall survival of the 
IFN-α treated group appears greater than anticipated.43 In 
recently reported phase 3 studies utilizing either sorafenib50 
or sunitinib,51 the increased PFS was not accompanied by sig-
nificant improvement in OS. In the trial comparing sunitinib 
and IFN-α,51 the differences in median OS in the intent to 
treat population was considered clinically significant, despite 
the P value of 0.051. When patients receiving secondary 
therapy were censored, significant differences were noted. It 
is likely the same confounding effects of secondary therapy 
are obscuring differences in survival in the recent phase 3 
bevacizumab trials. The available clinical data from three 
randomized clinical trials demonstrate therapy with sunitinib 
or bevacizumab plus IFN-α produces clinically relevant and 
a statistically significant increase in PFS compared to treat-
ment with IFN-α monotherapy.
Another unanswered question is how bevacizumab plus 
IFN-α therapy compares to the current front line treatment 
for metastatic RCC with sunitinib. The toxicity of sunitinib 
and bevacizumab are quite different, however, when IFN-α is 
included, the type and frequency of adverse events is modified. 
Currently, no phase 3 trials are planned or are in progress to 
compare efficacy and/or toxicity of these treatments, and 
therefore only indirect comparisons are possible. Coon et al53 
have utilized an indirect comparison methodology to assess the 
clinical effectiveness of sunitinib or bevacizumab plus IFN-a 
on PFS. A Bayesian Marko Chain Monte-Carlo sampling 
model in Win BUGS, with IFN-α as a common comparator 
was employed. The median PFS was significantly prolonged 
with either regimen compared to IFN-α. Indirect comparison 
suggested sunitinib was superior to bevacizumab plus IFN-α 
in terms of PFS (HR 0.796; 95% CI 0.63–1.0; P = 0.0272). 
Indirect survival comparisons have not yet been published.
Pharmacoeconomic assessment of targeted therapy as 
frontline treatment for metastatic RCC in the US and Sweden 
have been conducted utilizing indirect comparisons of sur-
vival.54 A Markov model was employed which simulated 
disease progression, adverse events, and survival with suni-
tinib versus sorafenib (US) or bevacizumab + IFN-α (both 
countries) among all patients. Results, in life-years (LY), 
progression-free LY (PFLY), quality-adjusted LY (QALY) 
gained, and treatment costs were developed employing 
deterministic and probabilistic analyses. Sunitinib was more 
effective and less costly than sorafenib (gains of 0.52 PFLY, 
0.16 LY, and 0.17 QALY and savings of $13,576 in the US) 
or bevacizumab + IFN-α (gains of 0.19 PFLY, 0.23 LY, and 
0.16 QALY in both countries and savings of $67,798 and 
$47,264 in the US and Sweden, respectively). Sunitinib was 
shown to be cost effective in comparison to other therapies 
in either the US or Sweden, despite significant differences in 
healthcare systems. In fact, sunitinib was found to be more 
effective and less costly compared to bevacizumab + IFN-α 
in the overall patient population in both countries.
These two regimens have different toxicity profiles, and 
therefore it has been hypothesized that costs for managing 
adverse events may be different. Mickisch et al55 used a linear 
decision analytical model to evaluate cost differences asso-
ciated with AE management during treatment with bevaci-
zumab plus IFN-α or sunitinib. Costs were calculated utilizing 
published data on health-care costs in the United Kingdom, 
Germany, France and Italy. The analysis suggested AE man-
agement costs were higher for sunitinib than for bevacizumab 
plus IFN-α. The average cost per patient for the management 
of grade 3–4 adverse events was decreased with bevacizumab 
plus IFN-α compared with sunitinib in all countries: United 
Kingdom €1475 versus €804, Germany €1785 versus €1367, 
France €2590 versus €1618, and Italy €891 versus €402. The 
main determinants were lymphopenia, neutropenia, throm-
bocytopenia, leukopenia fatigue, and asthenia for sunitinib, Cancer Management and Research 2010:2 92
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and for bevacizumab plus IFN-α, proteinuria, fatigue, 
asthenia, bleeding, anemia and gastrointestinal perforation. 
The authors concluded costs associated with adverse event 
management are lower for bevacizumab plus IFN-α than for 
sunitinib. It is unclear however, how therapy for lymphopenia 
can contribute significantly to treatment costs.
Similarly, as part of its health technology appraisal, the 
National Institute for Health and Clinical Excellence (NICE) 
in the UK also examined the cost-effectiveness of sunitinib 
and bevacizumab + IFN-α compared to IFN-α. Based on 
multiple considerations, including but not limited to cost-
effectiveness evidence, NICE recommended sunitinib as 
first-line treatment for people with advanced and/or meta-
static RCC who are suitable for cytokine therapy and who 
have an ECOG performance status of 0 or 1.56 The findings 
of the NICE cost-effectiveness analyses were also consistent 
with those reported by Benedict et al.54
Modeling treatments that have not been compared in 
randomized prospective trials, and subsequent extrapola-
tion of their outcomes, represents a significant challenge. 
Such findings may be considered robust if they are based 
on valid assumptions including treatment of similar patient 
populations. Studies such as these do however have significant 
limitations which include: (1) the confounding effect of 
crossover treatment on OS, which may inflate the outcome for 
a comparator group and underestimate the treatment benefit; 
(2) the uncertainty of assuming that the relative HR values 
for a given treatment, relative to comparator, remain constant 
over time; and (3) differences in survival between patients 
treated in clinical trials and in clinical practice.
Bevacizumab: future  
development in RCC
The future development of bevacizumab therapy in renal cell 
carcinoma is illustrated in Figure 5. The role of monotherapy 
remains to be fully assessed, and further development of 
combination strategies should be considered. The activity of 
bevacizumab plus IFN-α in patients with metastatic clear cell 
carcinoma has been clearly demonstrated, however, various 
dose levels of either agent, length of therapy, and the role 
of IFN-α in the combination have not been investigated 
adequately. The mechanisms responsible for the activity 
of this combination remain uncertain. Also, in view of the 
recognized lack of IFN-α dose-response in RCC, it may 
be that lower doses can decrease toxicity while preserving 
efficacy.
Since bevacizumab has been successfully combined 
with IFN-α, it is reasonable to investigate the combination 
Bevacizumab Monotherapy:
untreated patients
Standard
cytokine
regimen(s):
IL-2
VEGFR TKIs:
• Sunitinib
• Sorafenib
Unique settings:
1. CNS metastases
2. Renal/hepatic
    dysfunction
3. TKI refractory
4. Nonclear cell tumors
Adjuvant therapy Neoadjuvant setting
mTOR inhibitors:
• Temsirolimus
• Everolimus
Bevacizumab
Refractory RCC
• Multikinase inhibitors
• mTOR inhibitors
Combination regimens
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of bevacizumab with other cytokines, such as IL-2. 
High-dose IL-2 in combination with bevacizumab is under 
investigation.57 The rationale for this combination includes 
the possibility that bevacizumab may prevent much of the 
tumor-induced immunosuppression attributed to VEGF and 
thereby enrich the immune-enhancing effects of IL-2.58 In 
addition, IL-2 toxicity may be reduced by the vascular effects 
of bevacizumab on the vascular leak syndrome, and possibly 
allow more IL-2 to be administered with less toxicity. Beva-
cizumab 10 mg/kg IV every 2 weeks will be integrated with 
standard high dose IL-2 regimens with both PFS and OS as 
primary endpoints.
Investigation of bevacizumab in combination with low 
dose IL-2 has also been initiated. Garcia et al59 reported 
26 patients with untreated advanced RCC who received beva-
cizumab 10 mg/kg every 2 weeks, and IL-2 125,000 u/kg/day 
subcutaneously for 6 weeks, followed by a 2-week rest 
period. The median PFS for the group was 9.6 months (95% 
CI 4.1–16.9 months), and ORR 15%. An additional 38% of 
patients achieved tumor burden reduction of 30%. The most 
commonly reported treatment-related grade 3 toxicities were 
constitutional (fatigue, fever/chills) in 46% of patients, neutro-
penia in 11% and proteinuria in 12% of patients. The authors 
conclude that bevacizumab plus low dose IL-2 has modest 
clinical activity, and toxicity was largely IL-2 related without 
enhancement of bevacizumab-related adverse events.
Despite recent advances in the treatment of advanced 
RCC, not all patients respond, complete responses are 
uncommon, and tumor resistance to VEGF-targeted therapy 
generally develops. In view of these observations, maximal 
inhibition of the VEGF pathway, with combinations of  VEGF-
targeting agents having different mechanisms, may produce 
enhanced anti-tumor effects. Additive or synergistic VEGF 
blockade may be achieved through simultaneous targeting 
of the VEGF pathway. Bevacizumab leads to rapid clear-
ance of circulating VEGF, but is not known to affect VEGF 
bound to receptor, as the epitope on VEGF recognized by 
bevacizumab is in the VEGF-R binding region. Further, other 
pro-angiogenic molecules such as PDGF may contribute to 
the angiogenic phenotype of RCC and require inhibition. Suni-
tinib produces VEGF receptor blockade, however, circulating 
plasma VEGF increase and may expose tumors to the effects 
of VEGF in view of the intermittent schedule utilized.60 It is 
possible that maximal, constant and effective VEGF blockade 
can be produced with drugs inhibiting both the VEGF ligand 
and receptor, with enhanced anti-tumor effects. In view of 
this, combinations of bevacizumab with various TKIs such 
as sunitinib or sorafenib have been investigated.
Two phase 1 trials combining bevacizumab and sunitinib 
have have investigated the safety and maximum tolerated 
dose of this combination.61,62 Study design and eligibility 
criteria were different, with one trial61 restricted to advanced 
RCC patients, while in the second study,62 patients with 
refractory solid tumors were eligible. Antitumor activity 
was noted in both studies, but  grade 3 hypertension was 
noted in 45 to 60% of patients, and full doses of both agents 
(bevacizumab 10 mg/kg every 2 weeks, sunitinib 50 mg/day 
4/2 week schedule) were poorly tolerated. In the report from 
MSKCC,61 5/25 patients developed evidence of microangio-
pathic hemolytic anemia, in contrast to the second trial62 in 
which this was not observed. In view of these observations, 
further investigation of this combination in RCC utilizing full 
doses of both agents has not been recommended.61
The multikinase inhibitor sorafenib has also been investi-
gated in combination with bevacizumab in a series of two phase 
1 trials.63,64 Azad et al63 reported a group of 39 patients with 
advanced solid tumors who were treated in a phase 1 dose esca-
lation trial utilizing bevacizumab and sorafenib. Dose-limiting 
toxicity included grade 3 proteinuria and thrombocytopenia. 
Adverse events included hypertension, hand-foot syndrome, 
diarrhea, hepatic toxicity, and fatigue. Partial responses were 
seen in six (43%) of 13 patients with ovarian cancer (response 
duration range, 4 to 22 months) and 1 of 3 patients with renal 
cell cancer (response duration, 14 months). The majority 
(74%) of patients required sorafenib dose reduction. The 
investigators concluded combination therapy with sorafenib 
and bevacizumab has promising activity; however, dose reduc-
tions of both agents are required. Sosman et al64 also inves-
tigated this combination in 48 patients with RCC. Enhanced 
toxicity was observed, characterized by the sorafenib-related 
toxicity including severe hand–foot syndrome and functional 
stomatitis, and the bevacizumab related hypertension, and 
persistent proteinuria. Administration of the combination 
required decreasing both the bevacizumab (5 mg/kg IV every 
2 weeks) and sorafenib (200 mg by mouth once daily) dose 
levels. The clinical activity of the combination, was of inter-
est in RCC, with an ORR of 52%, and PFS of 14.0 months 
among the 48 RCC patients enrolled. In summary, the activity 
of the various bevacizumab TKI combinations is encouraging, 
but complete responses were not increased, and toxicity has 
required dose reductions of both agents. It remains uncertain 
whether combination approaches will be useful.
The second class of targeted agents that has been combined 
with bevacizumab, are the mTOR inhibitors temsirolimus 
and everolimus. Clinical trials in poor risk patients with 
temsirolimus,4 and in TKI refractory patients with everolimus65 Cancer Management and Research 2010:2 94
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demonstrate improvements in survival and PFS respectively. 
Preclinical studies66 have suggested combing an mTOR inhibi-
tor with bevacizumab may increase efficacy, and therefore this 
combination has been evaluated clinically.
A phase 2 study by Whorf et al65 investigated the combina-
tion of bevacizumab and everolimus. Patients with advanced 
RCC received bevacizumab 10 mg/kg IV every 2 weeks and 
everolimus 10 mg orally daily. Two groups of patients were 
treated: A-no prior treatment or B-prior sunitinib or sorafenib. 
Fifty-nine patients (30 to group A and 29 to group B) were 
enrolled. The best response in 48 evaluable patients was 
21% ORR and 69% stable disease/minor response. Toxicities 
included proteinuria (19% grade 3/4), fatigue (9% grade 3/4) 
mucositis/stomatitis (49% grade 3/4), hyperlipidemia (45% 
grade 3/4), nausea (40% grade 3/4) and hypertension (25%). The 
preliminary results suggest the combination of everolimus and 
bevacizumab administered at full doses has acceptable toxicity. 
A phase 2 randomized trial in which bevacizumab is combined 
with either IFN-α or everolimus (RECORD 2) is in progress.
Temsirolimus, the second mTOR inhibitor approved in 
advanced RCC, has also been combined with bevacizumab. 
A phase 1 trial67 utilizing both temsirolimus and bevacizumab 
was reported in a preliminary fashion. Dose-limiting toxicities 
encountered included grade 3 stomatitis and hypertryglyceri-
demia (1/6 patients at each dose level). The minimum tolerated 
dose was not reached, and the dose levels recommended for 
additional study were temsirolimus 25 mg/kg IV weekly and 
bevacizumab 10 mg/kg every 2 weeks. Twelve evaluable patients 
were treated, and 7/12 partial responses (58%) were reported. 
Based on these preliminary results, a randomized phase 3 
trial (INTORACT) is now ongoing comparing temsirolimus/
bevacizumab with bevacizumab/IFN-α. The studies with the 
mTOR inhibitors will provide information on the side effect 
profiles and efficacy of the mTOR inhibitor combinations 
investigated.Several other randomized trials evaluating various 
combinations are also underway. The BEST trial68 is a 4-arm 
phase 2 randomized trial examining doublets of sorafenib, 
bevacizumab, and temsirolimus plus bevacizumab alone. 
The TORAVA trial is a phase 2 trial comparing bevacizumab 
plus IFN-α, bevacizumab plus temsirolimus, and sunitinib. 
Enrolment is closed and results should be available shortly.69 
Currently most investigators regard combination therapy as 
investigational. Results of these ongoing trials are should define 
the efficacy an mTOR inhibitor plus bevacizumab.
Two additional areas of investigation to be considered 
are post-operative adjuvant therapy, and preoperative 
neoadjuvant therapy with bevacizumab. Currently, sev-
eral large multinational adjuvant trails utilizing the kinase 
inhibitors are in progress. When these results are available, 
comparison to bevacizumab is a strong consideration in view 
of the acceptable toxicity profile of this agent. In contrast, the 
potential role of bevacizumab in the neoadjuvant setting in 
patients with advanced RCC has been investigated. Jonasch 
et al70 assessed the safety and efficacy of presurgical treatment 
with bevacizumab in metastatic RCC patients, and whether 
this would assist in patient selection for cytoreductive nephrec-
tomy. 50 patients with clear cell carcinoma received either 
bevacizumab plus erlotinib (n = 23) or bevacizumab alone 
(n = 27) for 8 weeks followed by restaging. 42/50 patients 
underwent nephrectomy. Median PFS was 11.0 months (95% 
CI 5.5–15.6 months), and median OS 25.4 months (95% CI 
11.4 months to not evaluated). Wound dehiscence required 
treatment discontinuation for three and treatment delay for two 
other patients. The investigators concluded presurgical treat-
ment with bevacizumab yields clinical outcomes comparable 
to postsurgical treatment, but it may result in wound-healing 
delays. Prospective, randomized trials are now required to test 
the value of neoadjuvant bevacizumab.
Summary
Bevacizumab is a humanized monoclonal antibody that 
binds specifically to VEGF and inhibits VEGF activity. It 
has significant clinical benefits in patients with common 
solid tumors, including metastatic colorectal carcinoma,71 
metastatic breast carcinoma,72 and nonsmall cell lung carci-
noma.73 The available data now clearly demonstrate repro-
ducible effects and benefit in patients with metastatic RCC. 
A series of phase 2 trials demonstrated that bevacizumab 
monotherapy has activity and is well tolerated in patients with 
both therapy-naïve and pre-treated mRCC.33,42 In addition, 
experience from clinical trials indicates that bevacizumab 
does not increase the toxicity of concomitantly administered 
therapy.71–73 Bevacizumab and IFN-α suppress tumor growth 
by direct and indirect mechanisms, and these two agents 
may have complementary and synergistic effects when 
combined. The results from two recently completed phase 3 
trials, demonstrate bevacizumab plus IFN-α is a clinically 
useful treatment option for patients with good/intermediate 
risk metastatic clear cell carcinoma of the kidney.5,6 When 
this regimen is employed, it should be administered as 
described in the recently published studies.5,6 The choice of 
therapy for individual patients should be based on perceived 
risk/benefit ratio as well as the adverse event profile of the 
therapy. In the future comparative studies will be needed to 
define standards of care and assist physicians and patients 
with these therapeutic decisions.Cancer Management and Research 2010:2 95
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